文献速递临床试验与 GCP流行病学与生物统计

右美托咪定对阻塞性睡眠呼吸暂停患者术后谵妄影响的随机对照试验方案

The impact of dexmedetomidine on postoperative delirium in obstructive sleep apnea patients (DPOD-OSA): study protocol for a prospective randomized controlled trial.
PubMed 文献 · Trials · 2026-05-18

本研究为单中心前瞻性随机对照试验,拟纳入经STOP-Bang问卷筛查为中高危且AHI>5/h的OSA患者,随机分为高剂量右美托咪定组、低剂量右美托咪定组和对照组,主要结局为术后7天内或出院前谵妄发生率。

要点

  • OSA中高危患者术后谵妄风险较高,右美托咪定预防作用尚不明确。
  • 高剂量组右美托咪定负荷0.5 μg/kg后维持0.2~0.7 μg/kg/h,低剂量组维持0.5 μg/kg/h。
  • 主要结局用3D-CAM或CAM-ICU评估术后7天或出院前谵妄。

核心结论

  • 该试验旨在明确右美托咪定能否降低OSA患者术后谵妄发生率。

研究设计与样本

  • 单中心前瞻性随机对照试验,对象为择期腹腔镜手术且STOP-Bang评分≥3分、AHI>5/h的OSA患者。

关键数值与推荐

  • OSA诊断标准为AHI>5/h。
  • 高剂量右美托咪定组负荷0.5 μg/kg over 10 min,维持0.2~0.7 μg/kg/h;低剂量组维持0.5 μg/kg/h。
  • 术后谵妄采用3D-CAM或CAM-ICU连续评估7天或至出院。
  • 次要结局包括术后第1-7天静息及诱发疼痛、住院时长和30天内术后并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent studies suggest that patients at intermediate-high risk of obstructive sleep apnea (OSA) are at greater risk of developing postoperative delirium (POD). The administration of dexmedetomidine (DEX) is suggested to prevent POD in the normal population. However, few studies have investigated the impact of DEX on POD in OSA patients. METHODS/DESIGN: A prospective, randomized controlled trial will be conducted at a single center. Patients scheduled for elective laparoscopic surgery will be screened with the STOP-Bang questionnaire (SBQ). Patients who are intermediate-high risk for OSA (SBQ score ≥ 3) will be suggested to take a portable monitoring device for the diagnosis of OSA. Apner-Hyponea Index (AHI) values > 5/h are considered OSA. All the recruited OSA patients are randomly assigned to three treatment groups. The high dose of DEX group was treated with DEX at a loading dose of 0.5 μg/kg over 10 min followed by a maintenance dose of 0.2~0.7 μg/kg/h. The low dose of DEX group was treated with DEX at a maintenance dose of 0.5 μg/kg/h. The control group was not treated with DEX. POD was assessed using the 3-min diagnostic Confusion Assessment Method (3D-CAM) or the Confusion Assessment Method for Intensive Care Unit (CAM-ICU) for 7 consecutive days or until discharge. We used the Richmond Agitation and Sedation Scale (RASS) to assess the level of sedation and drowsiness. The primary outcome will be the occurrence of POD. The secondary outcomes include pain at rest and provoked pain during postoperative day 1-7, length of stay (LOS) and postoperative complications within 30 days. DISCUSSION: The result of this study will demonstrate whether the application of DEX could reduce the incidence of POD in OSA patients. We are of the conviction that the outcomes of this trial will afford a highly efficacious modality for preventing the occurrence of POD. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2500108088. Registered on 25 August 2025.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Li Y, Zhang R, Li N, et al. The impact of dexmedetomidine on postoperative delirium in obstructive sleep apnea patients (DPOD-OSA): study protocol for a prospective randomized controlled trial. Trials. 2026. PMID: 42144647. doi:10.1186/s13063-026-09791-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。